What is Yonalink?
Yonalink operates at the intersection of clinical research and health informatics, providing a sophisticated platform designed to migrate sensitive data from electronic health records into centralized research repositories. The company's core value proposition lies in its commitment to error-free, automated, and secure data transfer, which is essential for maintaining the integrity of clinical trials and longitudinal studies. By automating the ingestion of real-world evidence, Yonalink effectively reduces the administrative burden on medical institutions while enhancing the quality and accessibility of data for researchers.
In the current landscape, Yonalink occupies a vital niche, addressing the persistent challenges of interoperability and data standardization. Its platform is engineered to meet the rigorous validation requirements of the pharmaceutical and clinical research sectors, ensuring that data remains compliant with international standards while facilitating faster, more reliable insights for drug development and patient care optimization.
How much funding has Yonalink raised?
Yonalink has raised a total of $6M across 1 funding round:
Other Financing Round
$6M
Other Financing Round (2022): $6M with participation from European Union, Debiopharm Innovation Fund, and eHealth Ventures
Key Investors in Yonalink
European Union
A supranational political and economic union that supports large-scale innovation and research initiatives to foster economic cooperation and societal advancement across member states.
Debiopharm Innovation Fund
A strategic investment arm focused on identifying and supporting high-potential digital health and biotech startups that align with long-term pharmaceutical innovation goals.
eHealth Ventures
An early-stage digital health fund specializing in venture building, clinical integration, and commercial expansion for startups leveraging large-scale EMR data sets.
What's next for Yonalink?
With this major enterprise-level funding, Yonalink is poised to scale its operations and expand its footprint across international clinical research markets. The strategic focus will likely center on enhancing the platform's interoperability capabilities, deepening integrations with major electronic medical record systems, and strengthening its regulatory compliance framework to support larger-scale, multi-center trials.
The infusion of capital will also enable the company to bolster its professional team and invest in advanced data validation technologies. As Yonalink continues to mature, its trajectory suggests a move toward becoming an indispensable utility for global research organizations, potentially setting new benchmarks for how clinical data is harvested, validated, and utilized in the pursuit of medical innovation.
